Approximating Protein Flexibility through Dynamic Pharmacophore Models: Application to Fatty Acid Amide Hydrolase (FAAH)

A structure-based drug discovery method is described that incorporates target flexibility through the use of an ensemble of protein conformations. The approach was applied to fatty acid amide hydrolase (FAAH), a key deactivating enzyme in the endocannabinoid system. The resultant dynamic pharmacophore models are rapidly able to identify known FAAH inhibitors over drug-like decoys. Different sources of FAAH conformational ensembles were explored, with both snapshots from molecular dynamics simulations and a group of X-ray structures performing well. Results were compared to those from docking and pharmacophore models generated from a single X-ray structure. Increasing conformational sampling consistently improved the pharmacophore models, emphasizing the importance of incorporating target flexibility in structure-based drug design.

[1]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[2]  Daniele Piomelli,et al.  Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models , 2006, British journal of pharmacology.

[3]  Heather A Carlson,et al.  Protein flexibility is an important component of structure-based drug discovery. , 2002, Current pharmaceutical design.

[4]  Joseph Tam,et al.  Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects. , 2010, Chemistry & biology.

[5]  Hongfeng Deng,et al.  Recent advances in the discovery and evaluation of fatty acid amide hydrolase inhibitors , 2010, Expert opinion on drug discovery.

[6]  Raymond C Stevens,et al.  X-ray crystallographic analysis of alpha-ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase. , 2010, Journal of medicinal chemistry.

[7]  J A McCammon,et al.  Accommodating protein flexibility in computational drug design. , 2000, Molecular pharmacology.

[8]  Heather A. Carlson,et al.  Incorporating Dynamics in E. coli Dihydrofolate Reductase Enhances Structure-Based Drug Discovery , 2007, J. Chem. Inf. Model..

[9]  Stephen P. Mayfield,et al.  Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.

[10]  Marya Liimatta,et al.  Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. , 2007, Biochemistry.

[11]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[12]  Heather A Carlson,et al.  Exploring experimental sources of multiple protein conformations in structure-based drug design. , 2007, Journal of the American Chemical Society.

[13]  H. Carlson Protein flexibility and drug design: how to hit a moving target. , 2002, Current opinion in chemical biology.

[14]  Dale L Boger,et al.  Optimization of alpha-ketooxazole inhibitors of fatty acid amide hydrolase. , 2008, Journal of medicinal chemistry.

[15]  B. Cravatt,et al.  Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[17]  Zhihua Ma,et al.  Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH) , 2011, Proceedings of the National Academy of Sciences.

[18]  T. Nevalainen,et al.  Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors. , 2010, Current topics in medicinal chemistry.

[19]  Raymond C Stevens,et al.  Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. , 2009, Chemistry & biology.

[20]  Claudia Silva,et al.  Structure–Property Relationships of a Class of Carbamate‐Based Fatty Acid Amide Hydrolase (FAAH) Inhibitors: Chemical and Biological Stability , 2009, ChemMedChem.

[21]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.

[22]  Richard A. Lewis,et al.  Lessons in molecular recognition: the effects of ligand and protein flexibility on molecular docking accuracy. , 2004, Journal of medicinal chemistry.

[23]  David Butler,et al.  Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. , 2010, Life sciences.

[24]  Raymond C Stevens,et al.  Crystal structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: discovery of a deacylating water molecule and insight into enzyme inactivation. , 2010, Journal of molecular biology.

[25]  Giovanni Piersanti,et al.  Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates. , 2008, Journal of medicinal chemistry.

[26]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[27]  Giovanni Piersanti,et al.  Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. , 2004, Journal of medicinal chemistry.

[28]  Katrina W Lexa,et al.  Full protein flexibility is essential for proper hot-spot mapping. , 2011, Journal of the American Chemical Society.

[29]  Gilles Marcou,et al.  Hot-Spots-Guided Receptor-Based Pharmacophores (HS-Pharm): A Knowledge-Based Approach to Identify Ligand-Anchoring Atoms in Protein Cavities and Prioritize Structure-Based Pharmacophores , 2008, J. Chem. Inf. Model..

[30]  Henri Xhaard,et al.  Screening of Various Hormone‐Sensitive Lipase Inhibitors as Endocannabinoid‐Hydrolyzing Enzyme Inhibitors , 2009, ChemMedChem.

[31]  Hongma Sun,et al.  Pharmacophore-based virtual screening. , 2008, Current medicinal chemistry.

[32]  S. Teague Implications of protein flexibility for drug discovery , 2003, Nature Reviews Drug Discovery.

[33]  Alan Saghatelian,et al.  Functional disassociation of the central and peripheral fatty acid amide signaling systems. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Raymond C Stevens,et al.  Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling , 2002, Science.

[35]  Raymond C Stevens,et al.  Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by alpha-ketoheterocycle inhibitors revealed from cocrystal structures. , 2009, Journal of the American Chemical Society.

[36]  T. Cassano,et al.  Correction for Gobbi et al., Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Heather A Carlson,et al.  Protein flexibility and species specificity in structure-based drug discovery: dihydrofolate reductase as a test system. , 2007, Journal of the American Chemical Society.

[38]  Woody Sherman,et al.  Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation , 2009, J. Comput. Aided Mol. Des..

[39]  Gerard J Kleywegt,et al.  Limitations and lessons in the use of X-ray structural information in drug design , 2008, Drug Discovery Today.

[40]  Rommie E. Amaro,et al.  An improved relaxed complex scheme for receptor flexibility in computer-aided drug design , 2008, J. Comput. Aided Mol. Des..

[41]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[42]  Raymond C Stevens,et al.  Structure-guided inhibitor design for human FAAH by interspecies active site conversion , 2008, Proceedings of the National Academy of Sciences.

[43]  Woody Sherman,et al.  Novel Method for Generating Structure-Based Pharmacophores Using Energetic Analysis , 2009, J. Chem. Inf. Model..

[44]  Benjamin F. Cravatt,et al.  Potent and Selective α-Ketoheterocycle-Based Inhibitors of the Anandamide and Oleamide Catabolizing Enzyme, Fatty Acid Amide Hydrolase , 2007 .

[45]  Holger Gohlke,et al.  Target flexibility: an emerging consideration in drug discovery and design. , 2008, Journal of medicinal chemistry.